Merck & Co. (MRK) stock price is up over 19% over the past year. Mizuho's Mara Goldstein says that they maintain a buy rating on the MRK stock with a $100 price target. She states that the key takeaway from the cardiovascular event is potential revenue diversification drivers. Goldstein states that a $10B in peak revenue from the cardiovascular pipeline in the mid-2030s would be a strong offset. Also, the SPDR Biotech ETF (XBI) is down 21% year-to-date.
Market On Close
11 Apr 2022
SHARE
Market On Close
11 Feb 2023
Market On Close
10 Feb 2023
Trading 360
04 Mar 2023
Market On Close
24 Feb 2023
Trading 360
13 Jan 2023
Trading 360
03 Apr 2023